Supplementary Materials

Supplementary Table S1. Differentially expressed neutrophil-related genes identified between tumor and normal samples. Supplementary Table S2. Schoenfeld residual test for proportional hazards assumption Supplementary Table S3. Variance inflation factor (VIF) for multicollinearity assessment in the Cox regression model Supplementary Table S4. Comparison of immune phenotype scores between risk groups using Wilcoxon test Supplementary Table S5. Comparison of immune checkpoint–related gene expression between high- and low-risk groups using Wilcoxon test. Supplementary Table S6. Comparison of ESTIMATE scores between high- and low-risk groups using Wilcoxon test Supplementary Table S7: Chi-square test results for the distribution of NR and R across High and Low risk groups Supplementary Table S8. Wilcoxon test of immune cell composition and immune function between high- and low-risk groups Supplementary Table S9. Comparison of immune cell type proportions between high- and low-risk groups using Wilcoxon test Supplementary Table S10. Wilcoxon test of signature gene expression between clusters Supplementary Table S11. Wilcoxon test of risk scores between clusters Supplementary Table S12. Wilcoxon test of immune cell composition between clusters Supplementary Table S13. Wilcoxon test of immune cell composition and immune function between clusters Supplementary Table S14. Wilcoxon test of ESTIMATE scores and tumor purity between clusters Supplementary Table S15. Wilcoxon test of immune checkpoint gene expression between clusters Supplementary Table S16. Wilcoxon test of drug response between risk groups Supplementary Table S17. Gene–drug correlation analysis Supplementary Fig 1. Martingale residuals of multicox model. Supplementary Fig 2. Spearman correlation analysis of three signature genes. Supplementary Fig 3. AUC values for multiple models. Supplementary Fig 4. Risk scores for different cancer stages. Supplementary Fig 5. TMB of subtype.